OncoZenge: SEK7.5m convertible loan agreement with Linc - Redeye

Redeye comments on OncoZenge’s announcement of a SEK7.5m convertible loan agreement with major shareholder Linc. We view this as a strategic move that enhances the company’s financial flexibility ahead of the pivotal phase III trial for BupiZenge, further reinforcing recent momentum in funding and partnership execution.

Länk till analysen i sin helhet: https://www.redeye.se/research/1117152/oncozenge-sek7-5m-convertible-loan-agreement-with-linc?utm_source=finwire&utm_medium=RSS